Health Care

Benchmark analyst David Williams upgraded MACOM Technology Solutions Holdings Inc. (NASDAQ: MTSI) to Buy from Hold, with a price target of $92. The analyst is bullish on MTSI acquiring radio frequency business from Wolfspeed Inc (NYSE: WOLF) for $125 million. The...

The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD). Ingrezza is the only selective vesicular monoamine transporter 2 (VMAT2) inhibitor that offers an...

The healthcare technology company Cue Health Inc. (NASDAQ: HLTH) has become the first company to get De Novo authorization from the U.S. Food and Drug Administration (FDA) for an over-the-counter COVID-19 test — as well as being the first FDA De Novo authorization for any over-the-counter...

Needham raised the price target for CyberArk Software Ltd. (NASDAQ: CYBR) from $185 to $190. Needham analyst Alex Henderson maintained a Buy rating. CyberArk Software shares fell 0.3% to $161.50 in pre-market trading. Stephens & Co. increased Carrols Restaurant Group, Inc. (NASDAQ: TAST)...

The Dow Jones closed lower by over 400 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision....

The Nasdaq 100 closed higher on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company’s prospects or that they view the stock as being overpriced. Insider sales should not...

Needham raised the price target for MACOM Technology Solutions Holdings, Inc. (NASDAQ: MTSI) from $65 to $84. Needham analyst Quinn Bolton maintained a Buy rating. MACOM Technology shares rose 0.1% to $170.70 in pre-market trading. RBC Capital cut Sage Therapeutics, Inc. (NASDAQ: SAGE) price...

Needham raised the price target for Extreme Networks, Inc. (NASDAQ: EXTR) from $30 to $35. Needham analyst Alex Henderson maintained a Buy rating. Extreme Networks shares fell 1.7% to $29.70 in pre-market trading. Canaccord Genuity cut PayPal Holdings, Inc. (NASDAQ: PYPL) price target from $...

U.S. stocks closed mixed on Tuesday, as investors digested recent earnings reports and a fresh batch of economic data. Merck & Co Inc (NYSE: MRK) posted a narrower-than-expected quarterly loss, while sales topped estimates. Pfizer Inc (NYSE: PFE) reported a second-quarter adjusted EPS of $0.67...

Shares of health monitoring technology maker Masimo Corporation (NASDAQ: MASI) dropped 24% to $114.30 last week due to a second-quarter performance warning. They are at their lowest level since January 2019 — but according to Wall Street, could have healthy gains ahead.  The Irvine,...

Monday, the FDA approved Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) Ycanth (cantharidin) topical solution for molluscum contagiosum (molluscum) in adult and pediatric patients two years of age and older. Needham upgraded the stock to Buy from Hold with a price target...

Last month, the Food and Drug Administration (FDA) granted a landmark De Novo authorization for Cue Health’s (NASDAQ: HLTH) at-home COVID-19 test that delivers lab-quality results within 20 minutes. The move makes Cue Health the first company to receive De Novo authorization for an at-home...

Last month, the Food and Drug Administration (FDA) granted a landmark De Novo authorization for Cue Health’s (NASDAQ: HLTH) at-home COVID-19 test that delivers lab-quality results within 20 minutes. The move makes Cue Health the first company to receive De Novo authorization for an at-home...

BofA analyst Vivek Arya sees Q2 for U.S. semiconductor companies in line and modestly below Q3 on lukewarm macro, but CY24 EPS recovery could sustain longer-term stock momentum. The analyst upgraded Camtek Ltd (NASDAQ: CAMT) to Buy and raised the price target to $50 from $...

Needham analyst Mike Matson reiterated a Buy rating on Masimo Corporation (NASDAQ: MASI), lowering the price target to $136 from $207. The company recently reported Q2 2023 preliminary results and revised the 2023 outlook yesterday. MASI expects revenues of $453...